Justine Y. Bruce, MD close
Justine Y. Bruce, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Justine Y. Bruce, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Justine Bruce, MD, earned her medical degree at the University of Texas Southwestern Medical School in Dallas and completed her residency at the University of Texas Southwestern Medical School. Dr. Bruce completed a fellowship at the University of Chicago Hospitals and is board certified in internal medicine.


Medical Oncology

Head and Neck Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hospice and Palliative Medicine
Medical Oncology
Fellowship University of Chicago Hospitals, Chicago, IL
Residency University of Texas Southwestern Medical Center, Dallas, TX
Internship University of Texas Southwestern Medical Center, Dallas, TX
Medical School University of Texas Southwestern Medical Center, Dallas, TX

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
McDaniel NK Iida M Nickel KP Longhurst CA Fischbach SR Rodems TS Kranjac CA Bo AY Luo Q Gallagher MM Welke NB Mitchell KR Schulz AE Eckers JC Hu R Salgia R Hong S Bruce JY Kimple RJ Wheeler DL AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res . 2020 Aug 15;26(16):4349-4359
[PubMed ID: 32439698]
Bruce JY Bible KC Chintakuntlawar AV Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Thyroid . 2020 Aug 4;
[PubMed ID: 32664802]
Burr AR Harari PM Haasl AM Wieland AM Bruce JY Kimple RJ Hartig GK McCulloch TM Witek ME Clinical outcomes for larynx patients with cancer treated with refinement of high-dose radiation treatment volumes. Head Neck . 2020 Aug;42(8):1874-1881
[PubMed ID: 32057151]
Cosper PF Abel L Lee YS Paz C Kaushik S Nickel KP Alexandridis R Scott JG Bruce JY Kimple RJ Patient Derived Models to Study Head and Neck Cancer Radiation Response. Cancers (Basel) . 2020 Feb 12;12(2)
[PubMed ID: 32059418]
McHugh D Eisenberger M Heath EI Bruce J Danila DC Rathkopf DE Feldman J Slovin SF Anand B Chu R Lackey J Reyno L Antonarakis ES Morris MJ A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Invest New Drugs . 2019 Oct;37(5):1052-1060
[PubMed ID: 30725389]
Michaelson MD Gupta S Agarwal N Szmulewitz R Powles T Pili R Bruce JY Vaishampayan U Larkin J Rosbrook B Wang E Murphy D Wang P Lechuga MJ Valota O Shepard DR A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist . 2019 Sep;24(9):1151-e817
[PubMed ID: 31171735]
Burr AR Harari PM Ko HC Bruce JY Kimple RJ Witek ME Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer. Oral Oncol . 2019 May;92:52-56
[PubMed ID: 31010623]
Blitzer GC Rosenberg SA Anderson BM McCulloch TM Wieland AM Hartig GK Bruce JY Witek ME Kimple RJ Harari PM Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. Int J Radiat Oncol Biol Phys . 2018 Sep 1;102(1):146-148
[PubMed ID: 29980415]
Scarpelli M Rampurwala M Eickhoff J Carmichael L Heideman J Binger K Kolesar J Perlman S Harrow K Dukart G Liang C Jeraj R Liu G Bruce JY Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol . 2018 Aug;82(2):211-219
[PubMed ID: 29802443]
Ko HC Harari PM Sacotte RM Chen S Wieland AM Yu M Baschnagel AM Bruce JY Kimple RJ Witek ME Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas. J Cancer Res Clin Oncol . 2017 Nov;143(11):2341-2350
[PubMed ID: 28752235]
Prabakaran PJ Javaid AM Swick AD Werner LR Nickel KP Sampene E Hu R Ong IM Bruce JY Hartig GK Wieland AM Canon J Harari PM Kimple RJ Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clin Cancer Res . 2017 Oct 15;23(20):6044-6053
[PubMed ID: 28659312]
Swick AD Prabakaran PJ Miller MC Javaid AM Fisher MM Sampene E Ong IM Hu R Iida M Nickel KP Bruce JY Wheeler DL Kimple RJ Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. Mol Cancer Ther . 2017 Jul;16(7):1257-1268
[PubMed ID: 28446642]
Scarpelli M Bruce JY Carmichael L Eickhoff J Kolesar J Perlman S Jeraj R Liu G <sup>18</sup>F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemother Pharmacol . 2016 Dec;78(6):1245-1252
[PubMed ID: 27817059]
Sarantopoulos J Goel S Chung V Munster P Pant S Patel MR Infante J Tawbi H Becerra C Bruce J Kabbinavar F Lockhart AC Tan E Yang S Carlson G Scott JW Sharma S Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol . 2016 Nov;78(5):921-927
[PubMed ID: 27681579]
Tagawa ST Posadas EM Bruce J Lim EA Petrylak DP Peng W Kheoh T Maul S Smit JW Gonzalez MD De Porre P Tran N Nanus DM Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol . 2016 Nov;70(5):718-721
[PubMed ID: 26852075]
McKay RR Zurita AJ Werner L Bruce JY Carducci MA Stein MN Heath EI Hussain A Tran HT Sweeney CJ Ross RW Kantoff PW Slovin SF Taplin ME A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol . 2016 Jun 1;34(16):1913-20
[PubMed ID: 27044933]
Bruce JY LoRusso PM Goncalves PH Heath EI Sadowski E Shalinsky DR Zhang Y Traynor AM Breazna A Ricart AD Tortorici M Liu G A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemother Pharmacol . 2016 Mar;77(3):527-38
[PubMed ID: 26791870]
Bruce JY Scully PC Carmichael LL Eickhoff JC Perlman SB Kolesar JM Heideman JL Jeraj R Liu G Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol . 2015 Jul;76(1):187-95
[PubMed ID: 26021741]
Hussain M Corn PG Michaelson MD Hammers HJ Alumkal JJ Ryan CJ Bruce JY Moran S Lee SY Lin HM George DJ Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res . 2014 Aug 15;20(16):4218-27
[PubMed ID: 24965748]
Bruce JY Kolesar JM Hammers H Stein MN Carmichael L Eickhoff J Johnston SA Binger KA Heideman JL Perlman SB Jeraj R Liu G A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol . 2014 Mar;73(3):485-93
[PubMed ID: 24414551]